Evaluation of Non-Compressive Myelopathy in a Sample of Egyptian Patients

NCT ID: NCT05257330

Last Updated: 2022-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2022-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An observational study will be conducted in the Department of Neurology at AlAzhar University Hospitals To study the etiological factors of non-compressive myelopathy in a sample of Egyptian patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Myelopathy is a collective term referring to any pathologic condition or neurologic deficit related to the spinal cord. Myelopathies are a frequent and potentially disabling neurologic emergency.(Sarbu et al., 2019).

Diseases of the spinal cord often have devastating consequences and imaging studies are indispensable for their diagnosis. The diagnostic approach must be based on the clinical context, the time elapsed since the onset of symptoms and signs, and the imaging findings (Herrera et al., 2020).

Myelopathies may be compressive or non-compressive, regarding to subarachnoid space obstruction (Kundu et al., 2018).

Noncompressive myelopathy (NCM) is described as "spinal cord involvement without detectable clinical and radiological evidence of spinal cord compression causing neurological deficit (Thangaraj et al., 2019).

There have been a few studies that have investigated Noncompressive myelopathy (NCM) in Africa as part of nontraumatic myelopathy. With very few studies focusing on NMOSD, Most of them focus on extrinsic compression and infectious diseases as important causes of myelopathy (Musubire et al., 2021) Comprehensive data on Egyptian patients with Non-compressive myelopathy (NCM) in the light of newer diagnostic criteria and serological tests are lacking. No study has been conducted to study the clinico-radiological profile of Non-compressive myelopathy (NCM) so far. In this study, we are putting an effort to convey our experience on etiological pattern of Non-compressive myelopathy (NCM) with special reference to its radiological features.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelopathy Non-Compressive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CSF Examination

Lumbar puncture for CSF Examination

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients with acute, subacute, or chronic neurologic dysfunction (motor and sensory deficit, sphincteric involvement, and a well-defined upper sensory segmental level) consistent with myelopathy (with or without coexisting encephalopathy, neuropathy, or radiculopathy).

Exclusion Criteria

* 1\) Patients of myelopathy who did not undergo magnetic resonance imaging (MRI) of the spinal cord. 2) Spinal cord compression on MRI explaining patient's neurologic dysfunction. 3) History of previous trauma, acute coma and patients with definite cerebral symptoms incompatible with spinal pathology (e.g., aphasia, hemianopia, neglect, facial involvement). 4) Motor neuron disease (MND) 5)Degenerative ataxias.
Minimum Eligible Age

2 Months

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Al-Azhar University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Abdel-Ghaffar Ismail Fayed

Lecturer in Neurology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohie-eldin T Mohamed, Professor

Role: PRINCIPAL_INVESTIGATOR

Al-Azhar Faculty of medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Al-Hussein and Sayed Galal Hospitals

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Islam S Al-Emam, MSC

Role: CONTACT

+201027759946

Abdel-Ghaffar Iٍ Fayed, Lecturer

Role: CONTACT

+20 111 870 6806

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mohie-eldin T Mohamed, Professor

Role: primary

+20 115 736 3721

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0000044

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.